126 related articles for article (PubMed ID: 8740998)
1. Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies.
Gracon SI
Acta Neurol Scand Suppl; 1996; 165():114-22. PubMed ID: 8740998
[TBL] [Abstract][Full Text] [Related]
2. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.
Knapp MJ; Knopman DS; Solomon PR; Pendlebury WW; Davis CS; Gracon SI
JAMA; 1994 Apr; 271(13):985-91. PubMed ID: 8139083
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
[TBL] [Abstract][Full Text] [Related]
4. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group.
Foster NL; Petersen RC; Gracon SI; Lewis K
Dementia; 1996; 7(5):260-6. PubMed ID: 8872417
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
Farlow M; Gracon SI; Hershey LA; Lewis KW; Sadowsky CH; Dolan-Ureno J
JAMA; 1992 Nov; 268(18):2523-9. PubMed ID: 1404819
[TBL] [Abstract][Full Text] [Related]
6. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
Chatellier G; Lacomblez L
BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, placebo-controlled study of tacrine in Chinese patients with Alzheimer's disease.
Wong WJ; Liu HC; Fuh JL; Wang SJ; Hsu LC; Wang PN; Sheng WY
Dement Geriatr Cogn Disord; 1999; 10(4):289-94. PubMed ID: 10364647
[TBL] [Abstract][Full Text] [Related]
8. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group.
Knopman D; Schneider L; Davis K; Talwalker S; Smith F; Hoover T; Gracon S
Neurology; 1996 Jul; 47(1):166-77. PubMed ID: 8710072
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.
Farlow MR; Lahiri DK; Poirier J; Davignon J; Schneider L; Hui SL
Neurology; 1998 Mar; 50(3):669-77. PubMed ID: 9521254
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial.
Maltby N; Broe GA; Creasey H; Jorm AF; Christensen H; Brooks WS
BMJ; 1994 Apr; 308(6933):879-83. PubMed ID: 8173365
[TBL] [Abstract][Full Text] [Related]
11. Use of tacrine hydrochloride (Cognex) in private practice.
Howell GJ
Acta Neurol Scand Suppl; 1996; 165():123-7. PubMed ID: 8740999
[TBL] [Abstract][Full Text] [Related]
12. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration.
Burback D; Molnar FJ; St John P; Man-Son-Hing M
Dement Geriatr Cogn Disord; 1999; 10(6):534-40. PubMed ID: 10559571
[TBL] [Abstract][Full Text] [Related]
13. Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients.
Smith F
J Biopharm Stat; 1996 Mar; 6(1):59-67. PubMed ID: 8838779
[TBL] [Abstract][Full Text] [Related]
14. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.
Raskind MA; Sadowsky CH; Sigmund WR; Beitler PJ; Auster SB
Arch Neurol; 1997 Jul; 54(7):836-40. PubMed ID: 9236571
[TBL] [Abstract][Full Text] [Related]
15. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
[TBL] [Abstract][Full Text] [Related]
16. The use of survival analysis techniques in evaluating the effect of long-term tacrine (Cognex) treatment on nursing home placement and mortality in patients with Alzheimer's disease.
Smith F; Talwalker S; Gracon S; Srirama M
J Biopharm Stat; 1996 Nov; 6(4):395-409. PubMed ID: 8969976
[TBL] [Abstract][Full Text] [Related]
17. Tacrine in Alzheimer's disease.
Eagger SA; Levy R; Sahakian BJ
Lancet; 1991 Apr; 337(8748):989-92. PubMed ID: 1673209
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
19. Potential role for estrogen replacement in the treatment of Alzheimer's dementia.
Schneider LS; Farlow MR; Pogoda JM
Am J Med; 1997 Sep; 103(3A):46S-50S. PubMed ID: 9344406
[TBL] [Abstract][Full Text] [Related]
20. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.
Schneider LS; Farlow MR; Henderson VW; Pogoda JM
Neurology; 1996 Jun; 46(6):1580-4. PubMed ID: 8649552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]